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Granulocyte-macrophage colony-stimulating factor (GM-CSF) is
a haematopoietic growth factor acting on early multipotent
haematopoietic progenitors. GM-CSF regulates growth and differ-
entiation to macrophages or neutrophils (Metcalf, 1985; Sieff,
1987). In prospective randomized trials, GM-CSF has shown a
significant increase in neutrophil count and a significant reduction
of neutropenia duration after chemotherapy or autologous bone
marrow transplantation (Greenberg et al, 1996; Update of recom-
mendations for the use of haematopoietic colony-stimulating
factors: evidence-based clinical practice guidelines, 1996; Ravaud
et al, 1998). Moreover, GM-CSF induces mobilization and facili-
tates collection of peripheral blood stem cells (Demirer et al,
1996). 
Furthermore, there is some evidence that GM-CSF could have
antitumoural activity by enhancing immune response. In vitro
GM-CSF activates monocytes and macrophages to be cytotoxic to
human cell lines (Grabstein et al, 1986; Mazumder et al, 1990;
Williams et al, 1994). GM-CSF induces antibody-dependent cell-
mediated cytotoxicity (Kushner and Cheung, 1989; Mazumder
et al, 1990; Nagler et al, 1994). Proliferation of interleukin-2
driven T lymphocytes is enhanced in the presence of GM-CSF
(Santoli et al, 1988). 
In experimental animal models, GM-CSF has been found to
enhance the cytotoxicity of macrophages through production of
nitric oxide and free radicals (Hill et al, 1993). Moreover, gene
transfection of GM-CSF into tumour cells induces an antitumour
activity and protection of mice when challenged with tumours
(Dranoff et al, 1993). In humans, GM-CSF enhances cytotoxicity
of T lymphocytes CD3+ CD16- following bone marrow transplan-
tation (Richard et al, 1993). Antibody-dependent cell-mediated
cytotoxicity is also increased (Ragnhammar et al, 1993). The
ability to stimulate presentation of antigens is supported by GM-
CSF enhancing MHC class II expression on monocytes (Willman
et al, 1989). Moreover, GM-CSF is one of the main cytokines used
for producing ex vivo dendritic cells, which act as professional
antigen-presenting cells to induce T cell immune response
(Szabolcs et al, 1995; Bender et al, 1996; Coulon et al, 2000).
When GM-CSF was used during antitumoural vaccination with
peptide in patients with melanoma, it enhanced the immune
response through activation of CD4 + and CD8 + T cells (Jager
et al, 1996). 
The efficacy of GM-CSF as an antitumour agent has been
hypothesized in a prospective trial in patients with soft-tissue
sarcomas treated with chemotherapy in association with GM-CSF
for prevention of haematological toxicity. One study showed the
unexpected frequency of partial and complete response that could
account for an antitumoural effect of molgrastim (Edmonson et al,
1994, 1997). 
Prognosis of metastatic melanoma is poor and median survival
is 6–8 months (Balch et al, 1997). Palliative treatment is based
on chemotherapy with dacarbazine as first-line treatment (Ho,
1995). The arguments suggesting the efficacy of non-specific
immunotherapy in melanoma are that interleukin 2 has been
shown to induce clinical responses and long durable responses in
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Summary The potential antitumoural effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) led us to evaluate GM-CSF
alone or with dacarbazine (DTIC) in metastatic melanoma in first line randomized phase II. Treatment was arm A: GM-CSF: 5 µ g kg–1, bid, 14
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cycle. 32 patients (pts) were included, 15 pts in arm A and 17 in arm B. All pts had visceral metastatic sites. 9 had only one metastatic site.
The median number of cycles given was 2 in arm A and 3 in arm B. 100% and 89.4% of the planned dose of GM-CSF was given in arm A and
arm B respectively. No objective response was obtained. 19 pts experienced at least WHO grade 3 toxicity. All pts had fever, 29 had a
decrease in performance status and 23 had pain. Grade 3 toxicity were fever (38.7%), decrease in performance status (32.3%), pain (19.4%)
and dyspnoea (12.5%). In this study, GM-CSF alone or in association with DTIC did not induce any antitumoural activity with subsequent
toxicity. © 2001 Cancer Research Campaign http://www.bjcancer.com
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that interferon alpha induces a significant increase of disease-free
survival and a possible increase in survival when used as adjuvant
treatment (Kirkwood et al, 1996). 
Due to a possible antitumoural effect of GM-CSF through an
immune modulation and to low efficacy of chemotherapy in
metastatic melanoma, we conducted a multicenter randomized
trial comparing GM-CSF alone and GM-CSF associated with
dacarbazine in metastatic melanoma patients. 
PATIENTS AND METHODS 
Patients 
Adult patients under 70 years of age were eligible if they had
histologically confirmed melanoma with distant metastatic disease
that could be measured in 2 dimensions. Patients had an Eastern
Cooperative Oncology Group (ECOG) performance status ≤ 2. No
prior chemotherapy was allowed. Previous adjuvant interferon
alpha was allowed, but a delay of more than 6 months was
required before inclusion. Patients with central nervous system
metastases were excluded, except if they had been previously
treated (surgery and/or radiotherapy) and subsequently demon-
strated stable disease or no evidence of recurrence. Biological
inclusion criteria were leukocyte count ≥ 4 × 109 l–1, haematocrit
level ≥ 30%, platelet count ≥ 100 × 109 l–1, creatinine concentration
< 150 µ mol l–1 and transaminases < 2-fold the upper limit of
normal values except in the case of hepatic metastases where
< 5 fold the upper limit of normal values was required.
Furthermore, patients with severe infection or positivity for HIV
or hepatitis B or C were not eligible. Glucocorticosteroids were
not allowed. Patients did not have any additional malignancy other
than cervical carcinoma in situ or basal cell carcinoma. Pregnant
or lactating women were excluded. Patients had to give written
informed consent before entry into the trial. 
Pretreatment evaluation 
Clinical history and physical examination were recorded for all
patients. Before inclusion, patients had a staging including
thoracic and abdominal computed tomographic scans and a chest
X-ray. 
Study design and statistical considerations 
The study was an unblinded randomized phase II trial conducted
in 3 centres with no stratification. Registration and randomization
of eligible patients were performed at the data monitoring centre
of Institut Bergonié. The primary end point was the objective
response rate, and secondary end points were response duration,
toxicity and the response with dacarbazine alone after failure with
GM-CSF alone. 
An objective response rate of at least 20% would be of sufficient
interest to encourage further investigation of GM-CSF. The deter-
mination of the numbers of patients followed Gehan’s rules, which
indicates that including 14 patients gives a 95% chance of
detecting at least one response if the response rate was ≥ 20%
(Gehan, 1961). If at least one response occurred in the first 14
patients, it was planned to increase the number of patients up to a
total of 25 patients per arm to assess the response rate more
precisely. 
Treatment 
Eligible patients were randomly assigned to receive either GM-
CSF or GM-CSF with decarbazine (GM-CSF + DTIC). Dosage
and schedule of GM-CSF were based on the trial of Edmonson
et al (1994, 1997). Patients in the GM-CSF arm received subcuta-
neous GM-CSF at a dose of 5 µ g kg–1, bid for 14 consecutive days
every 21 days. Patients in the GM-CSF + DTIC arm received
DTIC at a dose of 800 mg m–2 on day one and subcutaneous GM-
CSF at a dose of 5 µ g kg–1, bid from day 2 to day 19 every 21 days. 
Response was assessed every 2 cycles. Work-up was identical to
the initial pretreatment evaluation. Each time stabilization or an
objective response occurred, 2 additional cycles of treatment were
planned up to a total of 12 cycles. 
Patients who progressed under GM-CSF alone received DTIC
at a dose of 800 mg m–2 on day one every 21 days. 
Evaluation of treatment 
The World Health Organization (WHO) criteria were used to
determine tumour response (Miller et al, 1981). Complete response
(CR) was defined as the complete disappearance of all measurable
and evaluable tumour sites for at least 4 weeks. The duration of
CR was calculated from the first date of documentation of CR to
the date of the first evaluation of disease progression. Partial
response (PR) was considered to be a ≥ 50% decrease in the sum
of products of the greatest perpendicular diameters that lasted for
at least 4 weeks, with no increase in known lesions and without
appearance of any new lesions. The duration of PR was calculated
from the first day of treatment. When the evaluation showed a
decrease in lesions < 50% and an increase < 25%, patients were
considered to have a stable disease (SD). Progressive disease (PD)
was considered to be when any lesion increased by ≥ 25% or when
a new lesion appeared. Patients who presented with a CR, PR or
SD were further evaluated every 2 to 3 months during the first year
and then every 4 to 6 months. Survival duration was evaluated
from the start of treatment to the date of the last contact or the date
of death. Toxicities encountered were classified according to the
World Health Organization grading system. 
RESULTS 
Patient characteristics 
32 patients were entered into this study (Table 1). All were evalu-
able for toxicity. 2 were considered not to be assessable for tumour
response: one had a grade 3 decrease in general status and went off
the study, and another refused to continue due to grade 3 pain after
one cycle of treatment. 
Administration of treatment and toxicity 
During treatment, the median dose of GM-CSF given in the GM-
CSF arm was 8960 µ g (range: 3300–11 200) corresponding to
100% of the planned dose, while the median dose of GM-CSF in
the GM-CSF + DTIC arm was 12 070 µ g (range: 7820–17 340),
accounting for 89.4% of the planned dose. The median number of
cycles received was 2 in the GM-CSF arm and 3 in the GM-CSF +
DTIC arm. 3 patients (20%) in the GM-CSF arm and 11 (64.7%)
in the GM-CSF + DTIC arm had a dose modification of GM-CSF
due to the induced toxicity. 6 patients (40%) in the GM-CSF arm
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or 4 toxicity (Table 2). 
Fever (32 patients), decrease in performance status (29 patients)
and pain (23 patients) were the most common adverse events
related to GM-CSF in the 2 groups. Only 3 patients had a grade 4
toxicity with anaemia (2 pts) and vomiting (1 pt), while 6 patients
in the GM-CSF arm and 10 in the GM-CSF + DTIC arm had a
grade 3 toxicity. The grade 3 toxicities were fever (6 patients in
both groups), pain (6 patients in the GM-CSF + DTIC arm; 1 in the
GM-CSF arm), decrease in performance status (7 patients in
the GM-CSF + DTIC arm; 3 in the GM-CSF arm), dyspnoea (4
patients in the GM-CSF arm) and thrombocytopenia (2 patients in
the GM-CSF + DTIC arm). 
Response to treatment and survival 
15 were included in the GM-CSF arm while 17 were included in
the GM-CSF + DTIC arm. Among 30 assessable patients, no
patient achieved an objective response. The best response
achieved was stable disease in 3 patients treated with GM-CSF +
DTIC, while all other patients already had tumour progression at
the evaluation done after 2 cycles of treatment. 
Among 8 patients who received DTIC alone after failure with
GM-CSF alone, one patient had a partial response. 
The median follow-up was 44.2 months. The median overall
survival was 6.3 months; 6.3 months in the GM-CSF arm and 7.3
months in the GM-CSF + DTIC arm. 
DISCUSSION 
In this study, GM-CSF induced no clinically evaluable antitu-
moural activity in patients with metastatic melanoma, given
either alone or in association with standard chemotherapy by
dacarbazine. This is the first study reporting the clinical evalua-
tion of GM-CSF alone or in association with chemotherapy in
metastatic melanoma patients. 
Other authors have shown a dramatic increase in response rate
with subcutaneous GM-CSF associated with chemotherapy (ifos-
famide, cisplatinum and doxorubicin) in patients with sarcoma
(Edmonson et al, 1994, 1997). However our study does not
confirm that GM-CSF increases the efficacy of a given
chemotherapy in metastatic solid tumours. 
In the phase I trial reported by Edmonson, 15 patients were
treated with chemotherapy supposed to induce 30% objective
response and complete response less than 5%. 14 patients had
metastatic localization. An objective response was seen in 7
patients. Furthermore, 5 patients had a complete remission and
another had a complete remission on metastatic site but not on the
primary tumour. The median duration of survival was 27 months,
longer than expected. Another phase II study from the EORTC
showed in 104 patients with metastatic sarcoma, that GM-CSF
added to escalated doses of chemotherapy could increase the
expected response rate to 45% and 10% of complete response
(Steward et al 1993); nevertheless, the impact of GM-CSF as well
as the dose intensity of chemotherapy are points to be debated.
Except for sarcomas, where the chemotherapy used is highly effec-
tive (objective response ≥ 30%), the wide literature so far on the
topic of GM-CSF given to prevent haemotoxicity, has not
provided data suggesting tumour efficacy of GM-CSF in
metastatic solid tumours. 
Our findings do not exclude the possibility of GM-CSF having
antitumoural activity on a lower tumour burden or in association
with a treatment devoted to triggering an immune response. This
hypothesis has since received confirmatory data on the ability of
GM-CSF to enhance immune response, even though there is not
yet a major impact on clinical outcome. The main focus of GM-
CSF activity on immune response has concerned the impact of
GM-CSF on the recruitment, activation and survival of dendritic
cells. It is known that GM-CSF given by intradermal route, leads
to local skin reactions, with a progressive accumulation of
Langerhans cells, while the subcutaneous route failed to do so
(Kaplan et al, 1992). It has been shown that GM-CSF enhances the
recruitment of dendritic cells, thereby increasing the number of
dendritic cells in regional lymph nodes, providing contact with
lymphocytes (Kass et al, 2001). In addition, GM-CSF enhances
the activation and survival of dendritic cells (Armitage, 1998).
Moreover, GM-CSF protects dendritic cells from apoptotic death
(Rabinovich et al, 1999). 
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Table 1 Patient characteristics 
Characteristics GM-CSF arm GM-CSF + DTIC arm
No. of patients 15 17 
Sex (male/female) 11/4 11/6 
Age, y. Median (range) 56 (35.5/70.5) 57 (36.6/67.6) 
Site of melanoma 
Cutaneous 11 12 
Ocular 1 2 
Visceral 1 0 
Unknown 2 3 
Time from diagnosis to metastasis 
Median (range) months 17.5 (0/89) 17.9 (0/140.5) 
ECOG performance status 
07 7  
17 8  
21 2  
Pts with visceral metastatic sites 15 17 
Sites of metastatic disease 
Lung 7 13 
Superficial lymph nodes 1 2 
Deep lymph nodes 6 9 
Liver 5 7 
Bone 2 5 
Others 9 4 
No of metastatic sites 
15 4  
26 6  
>2 4 7  
Table 2 Grade 3–4 WHO toxicity 
GM-CSF GM-CSF + DTIC
Toxicity Gr 3 Gr 4 Gr 3 Gr 4 
Fever 6 0 6 0 
Pain 1 0 6 0 
Decrease in performance status 3 0 7 0 
Dyspnea 0 0 4 0 
Skin disorders 0 0 0 0 
Nausea / vomiting 0 0 0 1 
Hypotension 0 0 0 0 
Neurological 3 0 0 0 
Anaemia 0 0 1 2 
Thrombocytopenia 0 0 2 0 
Hypercreatininaemia 0 0 0 0 The induction of an immune response by GM-CSF given intra-
dermally can be detected in eliciting local skin reaction and
strong DTH response, when used alone (Kaplan et al, 1992) or as
adjuvant therapy with peptide (Jäger et al, 1996; McNeel et al,
1999), a finding already demonstrated in experimental models
(Disis et al, 1996). 
Furthermore, there are arguments for stimulation of T lympho-
cytes. When the GM-CSF was given intralesionally in subcuta-
neous metastases, an increase in T cells, especially CD4+ cells
was noticed at the tumour site (Miller et al, 1981). Added to
vaccination procedures, either to peptide (Jäger et al, 1996) or to
irradiated autologous tumour cells (Si et al, 1996), GM-CSF
induced an increase in the CTL response. 
The increase in immune response, as shown biologically, has
been associated in clinical trials with tumour response. 
It has been shown that GM-CSF given intralesionally in subcuta-
neous metastases induced 3 partial responses in 13 patients with
metastatic melanoma (Miller et al, 1981). GM-CSF associated with
vaccination either with peptide or with irradiated autologous
tumour cells has shown to increase the clinical response to peptide
alone (Jager et al, 1996) or to irradiated autologous tumour cells
with BCG (Si et al, 1996). GM-CSF given intradermally with
peptides derived from Melan A/MART-1, tyrosinase and gp 100
in HLA-A2+ patients with metastatic melanoma induced one
complete response and 2 partial responses in 3 patients, while
vaccination with the same peptide alone induced only stabilization.
Furthermore, in 20 patients with metastatic melanoma treated by
vaccination with autologous irradiated tumour cells associated with
BCG and GM-CSF, 2 patients had a complete response and 2 others
a partial response, while a prior study by vaccination with autolo-
gous irradiated tumour cells associated with BCG did not show any
clinical response (Leong et al, 1999). In the latter study (Leong
et al, 1999), GM-CSF added to a treatment designed to trigger an
immune response, was effective for large metastatic tumour burden
from melanoma. 
On the other hand, another study demonstrated for efficacy
with GM-CSF in a lower tumour burden, while given as adjuvant
to surgery stage III or IV melanoma patients, but the results have
to be taken with caution (Spitler et al, 2000). 48 patients with
stage III or IV melanoma rendered disease-free by surgery
received GM-CSF in an adjuvant setting. Compared with matched
historical controls, overall survival and disease-free survival
were significantly prolonged in patients receiving GM-CSF. The
major concern of the Spitler study is that it is an uncontrolled
trial, even compared to matched historical controls. The
metastatic patients in it were from a very selected population,
rendered macroscopically disease-free by surgery, which is far
from the general population, especially patients included in our
study. No conclusion can be drawn out from the study, except
that immunobiologic modifier drugs are probably more active in
low tumour burden. 
The toxicity induced by the dosage and schedule in this
study was similar to that reported in the initial sarcoma
study with identical dosage and schedule (Edmonson et al, 1994,
1997). In both arms of our study, fever, decrease in performance
status and pain were the most frequent grade 3 side effects
for patients accounting for 38.7%, 32.3% and 19.4% respec-
tively. In the initial report (Edmonson et al, 1994), toxicities
were reported without grading of severity. Nevertheless, 10 of
the 15 patients had to receive prednisone to allow continuation of
treatment. 
CONCLUSION 
In this study of patients treated for metastatic melanoma, GM-CSF
alone or with dacarbazine, at the dosage and schedule used, did not
induce any objective response. Toxicity was severe with 19
patients (59.3%) presenting at least a WHO grade 3 toxicity.
Therefore, these findings do not support the contention that GM-
CSF has an antitumoural activity in metastatic solid tumours, at
least where there is a large tumour burden. 
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